RhumbLine Advisers
CRBP icon

RhumbLine Advisers’s Corbus Pharmaceuticals CRBP Stock Holding History

RhumbLine Advisers’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$192K Buy
20,463
+19,981
+4,145% +$189K ﹤0.01% 3301
2026
Q1 		$4.53K Hold
482
– – ﹤0.01% 3885
2025
Q4 		$3.92K Hold
482
– – ﹤0.01% 3940
2025
Q3 		$6.1K Hold
482
– – ﹤0.01% 3900
2025
Q2 		$3.33K Sell
482
-14,657
-97% -$106K ﹤0.01% 3950
2025
Q1 		$80.4K Buy
15,139
+25
+0.2% +$221 ﹤0.01% 3457
2024
Q4 		$178K Buy
15,114
+423
+3% +$7.09K ﹤0.01% 3257
2024
Q3 		$303K Buy
14,691
+588
+4% +$30.1K ﹤0.01% 3020
2024
Q2 		$638K Buy
+14,103
New +$593K ﹤0.01% 2495
2021
Q2 		– Sell
-3,363
Closed -$199K – 3015
2021
Q1 		$199K Sell
3,363
-67
-2% -$4.4K ﹤0.01% 2831
2020
Q4 		$129K Buy
3,430
+466
+16% +$17.4K ﹤0.01% 2935
2020
Q3 		$160K Sell
2,964
-431
-13% -$78.1K ﹤0.01% 2752
2020
Q2 		$855K Buy
3,395
+663
+24% +$134K ﹤0.01% 2106
2020
Q1 		$430K Buy
2,732
+37
+1% +$6.25K ﹤0.01% 2232
2019
Q4 		$441K Buy
2,695
+80
+3% +$11.8K ﹤0.01% 2421
2019
Q3 		$382K Sell
2,615
-13
-0.5% -$2.26K ﹤0.01% 2445
2019
Q2 		$546K Buy
2,628
+377
+17% +$80.7K ﹤0.01% 2328
2019
Q1 		$469K Buy
2,251
+95
+4% +$21K ﹤0.01% 2349
2018
Q4 		$378K Buy
2,156
+746
+53% +$149K ﹤0.01% 2426
2018
Q3 		$319K Sell
1,410
-107
-7% -$17.3K ﹤0.01% 2485
2018
Q2 		$230K Buy
1,517
+97
+7% +$17.6K ﹤0.01% 2670
2018
Q1 		$260K Buy
1,420
+185
+15% +$41.5K ﹤0.01% 2508
2017
Q4 		$263K Sell
1,235
-287
-19% -$61.4K ﹤0.01% 2520
2017
Q3 		$326K Buy
1,522
+23
+2% +$4.5K ﹤0.01% 2519
2017
Q2 		$283K Buy
+1,499
New +$294K ﹤0.01% 2585

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

RhumbLine Advisers's CRBP Position: Q2 2026 in Review

RhumbLine Advisers increased its Corbus Pharmaceuticals (CRBP) stake by 4,145% in Q2 2026, buying an estimated $189K and bringing the position to 20,463 shares worth $192K. The position accounts for ﹤0.01% of the portfolio, ranked #3301.

RhumbLine Advisers first reported a position in CRBP in Q2 2017 and has held it in 25 quarters since. The position peaked at $855K in Q2 2020. 97 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • RhumbLine Advisers held 20,463 shares of Corbus Pharmaceuticals worth $192K as of Q2 2026.
  • RhumbLine Advisers bought 19,981 Corbus Pharmaceuticals shares in Q2 2026, an estimated $189K.
  • Corbus Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3301 holding.
  • RhumbLine Advisers first reported a position in Corbus Pharmaceuticals in Q2 2017 and has held it in 25 quarters since.
  • RhumbLine Advisers's Corbus Pharmaceuticals position peaked at $855K in Q2 2020.
  • 97 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.